The present invention relates to an hexahydro-s-indacene compound of Formula (I) or its pharmaceutically acceptable salt wherein A is selected from the group consisting of (A1), (A2) and (A3) as defined in the claims. The compounds of the invention are medicaments for use in the treatment of immunopathologies related to the NLRP3 inflammasome, such as for example cancer, metabolic disorders, migraine, wound repair, neurodegenerative diseases and autoimmune diseases. The hexahydro-s-indacene compound of the invention is a selective inhibitor of the activation of the NLRP3 inflammasome and, as such, is capable of reducing the NLRP3-mediated production of interleukin-1β and interleukin 18 in mammalian cells and tissues.
Compounds as nlrp3 inflammasome inhibitors and their use as medicaments
Paolo Pinton;Giorgi Carlotta;Preti Delia;Pacifico Salvatore;Perrone Mariasole;Missiroli Sonia;Albanese Valentina.
2023
Abstract
The present invention relates to an hexahydro-s-indacene compound of Formula (I) or its pharmaceutically acceptable salt wherein A is selected from the group consisting of (A1), (A2) and (A3) as defined in the claims. The compounds of the invention are medicaments for use in the treatment of immunopathologies related to the NLRP3 inflammasome, such as for example cancer, metabolic disorders, migraine, wound repair, neurodegenerative diseases and autoimmune diseases. The hexahydro-s-indacene compound of the invention is a selective inhibitor of the activation of the NLRP3 inflammasome and, as such, is capable of reducing the NLRP3-mediated production of interleukin-1β and interleukin 18 in mammalian cells and tissues.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
